Prostate Cancer
Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI.
December 26, 2024
Long-Term Oncological Outcomes of Active Surveillance for Low-Risk Prostate Cancer Diagnosed During the MRI Era.
December 26, 2024
Occupational exposures of firefighting and prostate cancer risk in the Norwegian Fire Departments Cohort.
December 26, 2024
CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer.
December 25, 2024
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
December 25, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
December 25, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
December 24, 2024
Surface-Based Ultrasound Scans for the Screening of Prostate Cancer.
December 24, 2024
PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.
December 24, 2024
Socio-Economic Determinants of Cancer Screening Adherence Among Cancer Survivors: Analysis from 2020 Behavioral Risk Factor Surveillance System.
December 24, 2024
Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
December 23, 2024
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
December 23, 2024